BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Best J, Bilgi H, Heider D, Schotten C, Manka P, Bedreli S, Gorray M, Ertle J, van Grunsven LA, Dechêne A. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol 2016;54:1296-305. [PMID: 27936479 DOI: 10.1055/s-0042-119529] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
2 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Malov SI, Malov IV, Dvornichenko VV, Rasulov RI, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, Yushchuk ND. [Application of alpha-fetoprotein and osteopontin combination for early diagnosis of hepatocellular carcinoma associated with hepatitis C.]. Klin Lab Diagn 2019;64:607-12. [PMID: 31742954 DOI: 10.18821/0869-2084-2019-64-10-607-612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Kaur H, Dhall A, Kumar R, Raghava GPS. Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data. Front Genet 2019;10:1306. [PMID: 31998366 DOI: 10.3389/fgene.2019.01306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
5 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
6 Fang YS, Wu Q, Zhao HC, Zhou Y, Ye L, Liu SS, Li XX, Du WD. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1065-76. [PMID: 33691550 DOI: 10.1080/17474124.2021.1900731] [Reference Citation Analysis]
7 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
8 Ramai D, Tai W, Rivera M, Facciorusso A, Tartaglia N, Pacilli M, Ambrosi A, Cotsoglou C, Sacco R. Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma. Biomedicines 2021;9:184. [PMID: 33673113 DOI: 10.3390/biomedicines9020184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen S, Li J, Tan X, Xu Q, Mo Y, Qin H, Zhou L, Ma L, Wei Z. Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma: Evidence from literature and an original study. J Clin Lab Anal 2020;34:e23262. [PMID: 32167614 DOI: 10.1002/jcla.23262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
11 De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018;50:1115-1123. [PMID: 30217732 DOI: 10.1016/j.dld.2018.08.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
12 Schwarz J, Heider D. GUESS: projecting machine learning scores to well-calibrated probability estimates for clinical decision-making. Bioinformatics 2019;35:2458-65. [PMID: 30496351 DOI: 10.1093/bioinformatics/bty984] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
14 Cho HJ, Eun JW, Baek GO, Seo CW, Ahn HR, Kim SS, Cho SW, Cheong JY. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020;9:E281. [PMID: 31968558 DOI: 10.3390/jcm9010281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
15 Jones KR, Nabinger SC, Lee S, Sahu SS, Althouse S, Saxena R, Johnson MS, Chalasani N, Gawrieh S, Kota J. Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. J Surg Oncol 2018;118:431-9. [PMID: 30076741 DOI: 10.1002/jso.25156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e27673. [PMID: 34713864 DOI: 10.1097/MD.0000000000027673] [Reference Citation Analysis]
18 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
19 Wang X, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. Biomed Res Int 2020;2020:5087643. [PMID: 33015170 DOI: 10.1155/2020/5087643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Pirisi M, Leutner M, Romito R, Gaia S. Novel Calculators for Risk Stratification in Hepatocellular Carcinoma: A Concise Review. J Clin Gastroenterol 2020;54:789-94. [PMID: 32773489 DOI: 10.1097/MCG.0000000000001406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Alnasser S, Hussain SM, Alnughaymishi IM, Alnuqaydan AM. Pattern of food, drug and chemical poisoning in Qassim region, Saudi Arabia from January 2017 to December 2017. Toxicol Rep 2020;7:1438-42. [PMID: 33145179 DOI: 10.1016/j.toxrep.2020.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu M, Wu R, Liu X, Xu H, Chi X, Wang X, Zhan M, Wang B, Peng F, Gao X, Shi Y, Wen X, Ji Y, Jin Q, Niu J. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients. J Hepatocell Carcinoma 2020;7:219-32. [PMID: 33123501 DOI: 10.2147/JHC.S271790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, Tu J. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26:599-603. [PMID: 30661224 DOI: 10.1007/s12253-019-00585-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
24 Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
25 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
26 Song T, Wang L, Su B, Zeng W, Jiang T, Zhang T, Sun G, Wu H. Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma. J Int Med Res 2020;48:300060519889270. [PMID: 31852373 DOI: 10.1177/0300060519889270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
28 Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, Marquardt C, Wichert M, Toyoda H, Lange CM, Canbay A, Johnson P, Wedemeyer H, Best J. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients. Pharmaceuticals (Basel) 2021;14:735. [PMID: 34451832 DOI: 10.3390/ph14080735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lin H, Huang ZP, Liu J, Qiu Y, Tao YP, Wang MC, Yao H, Hou KZ, Gu FM, Xu XF. MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN. Sci Rep 2018;8:10461. [PMID: 29992971 DOI: 10.1038/s41598-018-28519-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
30 Zhou J, Zhu Y, Li Y, Liu K, He F, Xu S, Li X, Li L, Hu J, Liu Y. Combined detection of circulating tumor cells, α-fetoprotein heterogene-3 and α-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation. Infect Agent Cancer 2021;16:28. [PMID: 33971914 DOI: 10.1186/s13027-021-00367-2] [Reference Citation Analysis]
31 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Umeda S, Kanda M, Kodera Y. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma. Expert Rev Mol Diagn 2019;19:725-38. [PMID: 31248309 DOI: 10.1080/14737159.2019.1638254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol 2020;10:1316. [PMID: 32923383 DOI: 10.3389/fonc.2020.01316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
34 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
35 Zheng Ms B, Wang Ms H, Wang Ms JX, Liu Ms ZH, Zhang Md P, Zhang Md D. The Clinical Significance of RMI2 in Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211045496. [PMID: 34634948 DOI: 10.1177/15330338211045496] [Reference Citation Analysis]
36 Sun XL, Yao H, Men Q, Hou KZ, Chen Z, Xu CQ, Liang LW. Combination of acoustic radiation force impulse imaging, serological indexes and contrast-enhanced ultrasound for diagnosis of liver lesions. World J Gastroenterol 2017; 23(30): 5602-5609 [PMID: 28852319 DOI: 10.3748/wjg.v23.i30.5602] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
37 Cao X, Cao Z, Ou C, Zhang L, Chen Y, Li Y, Zhu B, Shu H. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients. Clin Res Hepatol Gastroenterol 2021;45:101583. [PMID: 33756265 DOI: 10.1016/j.clinre.2020.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang T, Zhang KH, Hu PP, Wan QS, Han FL, Zhou JM, Huang DQ, Lv NH. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases. Oncotarget 2017;8:97758-68. [PMID: 29228649 DOI: 10.18632/oncotarget.22050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A, Tokmak S, Ballı T, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Delik A, Arslan B, Doran F, Yilmaz S, Tokat Y. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018;15:453-464. [PMID: 29576865 DOI: 10.4172/clinical-practice.1000393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]